Skip to main content
Passage BIO, Inc. logo

Passage BIO, Inc. — Investor Relations & Filings

Ticker · PASG ISIN · US7027121000 US Professional, scientific and technical activities
Filings indexed 412 across all filing types
Latest filing 2025-06-26 Director's Dealing
Country US United States of America
Listing US PASG

About Passage BIO, Inc.

https://www.passagebio.com/

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for central nervous system (CNS) disorders. The company develops a portfolio of adeno-associated virus (AAV)-delivered therapeutics designed to treat rare, monogenic neurodegenerative diseases by delivering functional genes to patients with mutated or nonfunctional ones. Its lead clinical program, PBFT02, is a gene therapy being evaluated in a Phase 1/2 study for the treatment of Frontotemporal Dementia (FTD) with progranulin gene (GRN) mutations. Passage Bio aims to advance its pipeline to redefine the course of neurodegenerative conditions for patients.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-06-26 English
Regulatory Filings 2025
Regulatory Filings
2025-06-25 English
FORM 8-K
Regulatory Filings
2025-06-23 English
Director's Dealing 2025
Director's Dealing
2025-05-31 English
Director's Dealing 2025
Director's Dealing
2025-05-31 English
Director's Dealing 2025
Director's Dealing
2025-05-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.